Cabazitaxel*
-
API Product :
Cabazitaxel*
-
CEP :
-
-
WCC :
?
-
Therapeutic Use :
Antineoplastics
-
Originator :
SANOFI AVENTIS PHR
-
CAS No. :
183133-96-2
-
Trade Name. :
JEVTANA KIT
-
Molecular Weight :
835.93 g/mol
-
Molecular Formula :
C45H57NO14
Application
Cabazitaxel (Jevtana) is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel- containing treatment regimen.
General Description
Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid.[1] It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.